Search Result
Results for "
HIV
" in MedChemExpress (MCE) Product Catalog:
1031
Inhibitors & Agonists
9
Biochemical Assay Reagents
77
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-147314
-
|
HIV
Src
|
Infection
|
HIV-IN-6 is a HIV-Ⅰ viral replication inhibitor by targeting Src family kinases (SFK) that interact with Nef protein of the virus, such as Hck .
|
-
-
- HY-163161
-
|
HIV
|
Infection
|
HIV-1 inhibitor-62 (compound 6) is an HIV-1 inhibitor that can be used in antiviral research .
|
-
-
- HY-163085
-
|
HIV
|
Infection
|
HIV capsid modulator 1(compound 21a2) is a potent HIV capsid modulator. HIV capsid modulator 1 is a quinazolin-4-one-bearing phenylalanine derivative. HIV capsid modulator 1 has antiviral activities against both HIV-1 and HIV-2 .
|
-
-
- HY-N12082
-
|
HIV
|
Infection
|
HIV-IN-8 (Compound 9) is a HIV inhibitor. HIV-IN-8 inhibits HIV replication with an EC50 of 13 μg/mL .
|
-
-
- HY-163852
-
-
-
- HY-149350
-
|
HIV
|
Infection
|
HIV-1 inhibitor-57 (Compound 12g) is a HIV inhibitor. HIV-1 inhibitor-57 is active against wild-type and five prevalent NNRTI-resistant HIV-1 strains with EC50 values ranging from 0.024 to 0.0010 μM. HIV-1 inhibitor-57 forms additional interactions with residues around the binding site in HIV-1 RT .
|
-
-
- HY-P4018
-
|
HIV Protease
|
Infection
|
HIV Protease Substrate IV is a substrate of HIV protease. HIV Protease Substrate IV can be used to measure the activity of HIV (human immunodeficiency virus) -1 protease .
|
-
-
- HY-147807
-
|
HIV
Cytochrome P450
|
Infection
|
HIV-1 inhibitor-40 (Compound 4ab) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1 with an EC50 of 1.9 nM. HIV-1 inhibitor-40 displays weak CYP sensitivity with IC50 values of 5.16 μM and 4.51 μM against CYP2C9 and CYP2C19, respectively. HIV-1 inhibitor-40 has no apparent in vivo acute toxicity .
|
-
-
- HY-159092
-
|
HIV Integrase
|
Infection
|
HIV-1 integrase inhibitor 13 (Compound 15) is an inhibitor for HIV-1 integrase with an IC50 of 1.8 nM. HIV-1 integrase inhibitor 13 inhibits the HIV-1 WT and HIV-1 T125A, with IC50 of 21 and 580 nM, respectively .
|
-
-
- HY-150549
-
|
HIV Protease
HIV
|
Infection
Inflammation/Immunology
|
HIV-1 protease-IN-6 (compound 17d) is a potent HIV-1 protease inhibitor, with an IC50 of 21 pM and a Ki of 4.7 pM, respectively. HIV-1 protease-IN-6 exhibits potent antiviral activity to DRV (darunavir)-resistant variant, even more than wild type virus .
|
-
-
- HY-149866
-
|
Cytochrome P450
HIV
Reverse Transcriptase
|
Infection
|
HIV-1 inhibitor-58 (Compound 10c) is a broad-spectrum antiviral agent. HIV-1 inhibitor-58 is a non-nucleoside reverse transcriptase inhibitor. HIV-1 inhibitor-58 inhibits WT strain IIIB, NNRTI-resistant strains (such as K103N and E138K) in MT-4 cells, with EC50 less than 50 nM. HIV-1 inhibitor-58 also inhibits CYP2C9 and CYP2C19 (IC50: 2.06 μM, 1.91 μM). HIV-1 inhibitor-58 can be used for HIV infection reserch .
|
-
-
- HY-P2344
-
|
HIV Protease
|
Infection
|
HIV Protease Substrate 1, a fiuorogenic HIV protease substrate, can be used to study enzymatic activity of HIV protease .
|
-
-
- HY-P10252
-
|
HIV
|
Inflammation/Immunology
|
HIV gp120 421-438 is HIV antigen fragments, that conjugates with keyhole limpet hemocyanin (KLH) and generates specific anti-HIV antibody .
|
-
-
- HY-P10250
-
|
HIV
|
Inflammation/Immunology
|
HIV gp120 308-331 is HIV antigen fragments, that conjugates with keyhole limpet hemocyanin (KLH) and generates specific anti-HIV antibody .
|
-
-
- HY-P2344A
-
|
HIV Protease
|
Infection
|
HIV Protease Substrate 1 TFA, a fiuorogenic HIV protease substrate, can be used to study enzymatic activity of HIV protease .
|
-
-
- HY-W325699
-
|
HIV
Reverse Transcriptase
|
Infection
|
HIV-1 inhibitor-48 (compound 13o) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) and exhibits anti-HIV-1 activity .
|
-
-
- HY-P3980
-
|
HIV Protease
|
Infection
|
HIV-1, HIV-2 Protease Substrate is the substrate of HIV-1, HIV-2 protease. And there are 4 residues for conservative substitutions of the substrate binding residues of HIV-1 and HIV-2 protease .
|
-
-
- HY-161986
-
|
HIV
|
Infection
|
HIV-1 inhibitor-74 (compound 10c) is a potent HIV-1 inhibitor with an EC50 value of 0.0047 µM for HIV-1 IIIB. HIV-1 inhibitor-74 shows cytotoxicity. HIV-1 inhibitor-74 inhibits WT HIV-1 RT activity with an IC50 value of 0.134 µM. HIV-1 inhibitor-74 shows broad-spectrum anti HIV-1 activity .
|
-
-
- HY-143478
-
|
HIV
|
Infection
|
HIV-IN-1 (Compound 50) is a potent inhibitor of HIV. HIV-IN-2 has the potential for the research of HIV infection .
|
-
-
- HY-146363
-
|
HIV
|
Infection
|
HIV-IN-4 (Compound 12) is a potent inhibitor of HIV. HIV-IN-4 shows promising anti-HIV activities .
|
-
-
- HY-143479
-
|
HIV
|
Infection
|
HIV-IN-2 (Compound 100) is a potent inhibitor of HIV. HIV-IN-2 has the potential for the research of HIV infection .
|
-
-
- HY-120812
-
|
HIV Protease
|
Infection
|
HIV-IN-11 is part of the hydroxylaminoglutaramide (HAPA) transition state isomeric series of HIV protease inhibitors and is a potent and selective inhibitor of HIV-1 protease. HIV-IN-11 competitively inhibits HIV-1 PR (Ki: 0.049 nM) and potently inhibits replication of HIV(IIIb)-infected MT4 lymphocytes at concentrations of 25.0-50.0 nM. HIV-IN-11 displays a longer half-life than indinavir sulfate in animal models and serves as a promising second-generation HIV protease inhibitor .
|
-
-
- HY-162077
-
|
HIV
|
Infection
|
HIV-IN-10 is a HIV-1 latency reversing agent .
|
-
-
- HY-152539
-
|
HIV
|
Infection
|
HIV-1 inhibitor-54 is a potent HIV-1 inhibitor. HIV-1 inhibitor-54 has anti-HIV activity in MT-4 cells against WT HIV-1 (strain IIIB) with an EC50 value of 0.032 μM. HIV-1 inhibitor-54 can be used for the research of virus infection .
|
-
-
- HY-169335
-
|
HIV
|
Infection
|
HIV-1 inhibitor-77 (compound 13) is a HIV-1 inhibitor. HIV-1 inhibitor-77 can neutralize all three tested viruses with the IC50 values of 0.14 μM, 8.28 μM and 2.92 μM for HIV-1CH58TF , HIV-1 JRFL and HIV-1 AD8, respectively .
|
-
-
- HY-146089
-
|
HIV
|
Infection
|
HIV-1 inhibitor-32 (compound 3c) is a potent HIV-1 inhibitor with an IC50 value of 34 nM for WT HIV-1. HIV-1 inhibitor-32 can be used for researching AIDS .
|
-
-
- HY-163362
-
|
Reverse Transcriptase
PKC
HIV
|
Infection
|
HIV-1 inhibitor-65 (compound 3c) is an inhibitor of HIV-1 (EC50: 2.9 nM) and an activator of protein kinase C (PKC). HIV-1 inhibitor-65 inhibits syncytium formation (EC50: 7.0 nM) and inhibits HIV-1 entry and HIV-1 reverse transcriptase .
|
-
-
- HY-P4543
-
-
-
- HY-142468
-
|
HIV
|
Infection
|
HIV-1 inhibitor-12 is potent HIV-1 inhibitor. HIV-1 inhibitor-12 inhibits HIV-1 capsid protein polymerization with an IC50 of 9 nM (WO2021104413A1, compound 1-1a) .
|
-
-
- HY-152560
-
|
HIV
|
Infection
|
HIV-1 inhibitor-55 (compound 4d) inhibits WT HIV-1 with an EC50 value of 8.6 nM. HIV-1 inhibitor-55 also shows inhibitory potency against single and double HIV-1 mutants. HIV-1 inhibitor-55 can be used for the research of virus infection .
|
-
-
- HY-163177
-
|
HIV
|
Infection
|
HIV-1 inhibitor-63 (compound S17) is a potent HIV-1 inhibitor. HIV-1 inhibitor-63 inhibits integrase-Ku70 complex formation with an IC50 value of 12 µM. HIV-1 inhibitor-63 inhibits HIV-1 post-integration DNA repair .
|
-
-
- HY-152157
-
|
HIV
|
Infection
|
HIV-1 inhibitor-52 is a potent broad-spectrum HIV-1 activity inhibitor with EC50s of 1.6 nM-6.4 nM for WT HIV-1, HIV-1 V370A, HIV-1 ΔV370, HIV-1 V362I/V370A, HIV-1 T332S/V362I/prR41G, HIV-1 A326T/V362I/V370A, HIV-1 R361K/V362I/L363M .
|
-
-
- HY-146973
-
|
HIV
|
Infection
|
HIV-IN-3 (Compound 22a) is a potent inhibitor of HIV with an IC50 of 1.5 μM. HIV-IN-3 has the potential for the research of HIV-related diseases .
|
-
-
- HY-132291
-
|
HIV
|
Infection
|
HIV-1 inhibitor-8 is an orally active, low-toxicity and potent HIV‑1 non-nucleoside reverse transcriptase inhibitor (NNRTI). HIV-1 inhibitor-8 yields exceptionally potent antiviral activities (EC50=4.44~54.5 nM) against various HIV‑1 strains. The IC50 of HIV-1 inhibitor-8 against WT HIV-1 reverse transcriptase is 0.081 μM .
|
-
-
- HY-149991
-
|
HIV
|
Infection
|
HIV-1 inhibitor-56 (compound 12126065) is a potent HIV-1 non-nucleoside reverse transcriptase inhibitor. HIV-1 inhibitor-56 has antiviral activity against wild-type HIV-1 in TZM cells with an EC50 value of 0.24 nM. HIV-1 inhibitor-56 penetrates the blood-brain barrier .
|
-
-
- HY-150697
-
|
HIV
|
Others
|
HIV-1 inhibitor-44 (compound 11l) is a HIV-1 reverse transcriptase inhibitor. HIV-1 inhibitor-44 shows inhibitory activity against wild-type HIV-1 strain with an EC50 value of 0.209 μM .
|
-
-
- HY-163666
-
|
HIV
PKC
|
Infection
|
HIV-1 inhibitor-68 (compound 26) is a protein kinase C (PKC) activator derivative with reversal activity in HIV-1 latency. HIV-1 inhibitor-68 may be able to eliminate cells latently infected with HIV-1, .
|
-
-
- HY-146088
-
|
HIV
|
Infection
|
HIV-1 inhibitor-31 (compound 4) is a potent HIV-1 inhibitor. HIV-1 inhibitor-31 can be used for researching AIDS .
|
-
-
- HY-144112
-
|
HIV
|
Infection
|
HIV-1 inhibitor-13 (compound 16c) is a orally active and potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI), with IC50 of 0.14 μM (HIV-1 RT). HIV-1 inhibitor-13 shows activity against a panel of HIV-1 resistant strains, with EC50 values of 2.85-18.0 nM .
|
-
-
- HY-142253
-
|
HIV
|
Infection
|
HIV-1 inhibitor-10 is a nanomolar HIV-1 maturation inhibitor.
|
-
-
- HY-146352
-
|
HIV
|
Infection
Inflammation/Immunology
|
HIV-1 inhibitor-28 (compound 14j2) is a highly potent and selective HIV-1 inhibitor with an EC50 of 58 nM for WT HIV-1 strain and an IC50 of 3.37 μM for HIV-1 WT reverse transcription (RT). HIV-1 inhibitor-28 exhibits relatively low cytotoxicity in MT-4 cells (CC50 = 38.6 μM). HIV-1 inhibitor-28 can be used for researching AIDS .
|
-
-
- HY-168189
-
|
HIV
|
Infection
|
HIV-1 inhibitor-76 (compound 9t-2) is a non-nucleoside reverse transcriptase inhibitor of HIV-1. HIV-1 inhibitor-76 can be used in anti-HIV research .
|
-
-
- HY-152200
-
|
HIV Protease
Reverse Transcriptase
|
Infection
Inflammation/Immunology
|
HIV-1 inhibitor-53 is a dual HIV-1 protease and reverse transcriptase inhibitor. HIV-1 inhibitor-53 inhibits HIV-1 protease (PR) and reverse transcriptase (RT) activity with IC50 values of 1.93 nM and 2.35 μM, respectively. HIV-1 inhibitor-53 can be used for the research of acquired immune deficiency syndrome (AIDS) .
|
-
-
- HY-146091
-
|
HIV
|
Infection
|
HIV-1 inhibitor-34 (compound 5q) is a potent and selective HIV-1 inhibitor with an EC50 of 6.4 nM for HIV-1 and a CC50 of 16 μM in MT-4 cells. HIV-1 inhibitor-34 can be used for researching AIDS .
|
-
-
- HY-146090
-
|
HIV
|
Infection
|
HIV-1 inhibitor-33 (compound 5n) is a potent and selective HIV-1 inhibitor with an EC50 of 8.6 nM for HIV-1 and a CC50 of 18 μM in MT-4 cells. HIV-1 inhibitor-33 can be used for researching AIDS .
|
-
-
- HY-P3934
-
|
HIV Protease
|
Infection
|
HIV Protease Substrate I is a chromogenic substrate of HIV-1 protease. HIV Protease Substrate I has the cleavage site of HIV protease .
|
-
-
- HY-147553
-
|
HIV
|
Infection
|
HIV-1 inhibitor-36 (Compound 2) is a potent HIV-1. HIV-1 inhibitor-36 has the potential for further development as novel latency reversing agents .
|
-
-
- HY-147554
-
|
HIV
|
Infection
|
HIV-1 inhibitor-37 (Compound 83) is a potent HIV-1. HIV-1 inhibitor-37 has the potential for further development as novel latency reversing agents .
|
-
-
- HY-147555
-
|
HIV
|
Infection
|
HIV-1 inhibitor-38 (Compound 91) is a potent HIV-1. HIV-1 inhibitor-38 has the potential for further development as novel latency reversing agents .
|
-
-
- HY-144113
-
|
HIV
|
Infection
|
HIV-1 inhibitor-14 (compound 14b) is a highly potent and broad-spectrum HIV-1 non-nucleoside reverse transcriptase (RT) inhibitor with an EC50 of 0.14 μM for HIV-1 RT. HIV-1 inhibitor-14 has inhibitory activity against HIV-1 WT and resistant strains with EC50s of 5.79 ~ 28.3 nM .
|
-
- HY-147723
-
|
HIV
|
Infection
|
HIV-1 inhibitor-39 (compound 3c) is a potent HIV-1 inhibitor with an EC50 of >112.88 µM. HIV-1 inhibitor-39 shows anti-RT (HIV-1 reverse transcriptase) activities with an IC50 of 15.75 µM. HIV-1 inhibitor-39 shows cytotoxicity for MT-4 cells with an CC50 of 112.9 µM .
|
-
- HY-147904
-
|
HIV
|
Infection
|
HIV-IN-5 (compound 5r) is a potent HIV-1 inhibitor, with an IC50 of 0.16 μM. HIV-IN-5 shows inhibition of HIV DNA-dependent DNA polymerization activity, with an IC50 of 2.18 μM. HIV-IN-5 can bind to NNIBP (NNRTIs (non-nucleoside reverse transcriptase inhibitors) binding pocket) .
|
-
- HY-134851
-
|
HIV
|
Infection
|
HIV-1 inhibitor-6 (compound 9), a diheteroarylamide-based compound, is a potent HIV-1 pre-mRNA alternative splicing inhibitor. HIV-1 inhibitor-6 blocks HIV replication. HIV-1 inhibitor-6 is active against wild-type HIV-1IIIB (subtype B, X4-tropic) and HIV-1 97USSN54 (subtype A, R5-tropic) with EC50s of 0.6 μM and 0.9 μM, respectively. HIV-1 inhibitor-6 inhibits HIV strains resistant to agents targeting HIV reverse transcriptase, protease, integrase, and coreceptor CCR5 with EC50s ranging from 0.9 to 1.5 μM .
|
-
- HY-147552
-
|
HIV
|
Infection
|
HIV-1 inhibitor-35 (compound 74) is a potent HIV-1 inhibitor with EC50s of 80 nM and 70 nM for LTR and CMV in HEK293 cells, respectively. HIV-1 inhibitor-35 has inhibitory activity against liver cancer cell HepG2 with a CC50 of 40 nM. HIV-1 inhibitor-35 can be used as HIV-1 latency reversing agent .
|
-
- HY-146018
-
|
HIV
|
Infection
|
HIV-1 inhibitor-23 (compound 12a) is a highly potent HIV-1 non-nucleoside reverse transcriptase inhibitor, with EC50s of 24.9 nM and 10.4 nM for HIV-1 WT and HIV-1 K103N, respectively. HIV-1 inhibitor-23 has low cytotoxicity (CC50 > 221 μM) and a favorable in vitro microsomal stability .
|
-
- HY-159984
-
|
HIV
|
Infection
|
HIV-1 inhibitor-78 (compound 15f) is a potent and broad-spectrum non-nucleoside reverse transcriptase inhibitor, with an EC50 of 3 nM for wild-type HIV-1. HIV-1 inhibitor-78 can be used for the research of HIV infection .
|
-
- HY-P1586
-
HIV-1 rev Protein (34-50)
|
HIV
|
Infection
|
HIV-1 Rev (34-50) is a 17-aa peptide derived from the Rev-responsive element (RRE)-binding domains of Rev in HIV-1, with anti-HIV-1 activity.
|
-
- HY-147903
-
|
HIV
|
Infection
|
HIV-1 inhibitor-42 (compound 5b) is a potent HIV-1 inhibitor, with an IC50 of 0.06 μM. HIV-1 inhibitor-42 inhibits HIV-1 RT RNA-dependent DNA polymerase and DNA-dependent DNA polymerase, with IC50 values of 0.518 and 0.072 μM .
|
-
- HY-164201
-
|
HIV
|
Infection
|
HIV-1 inhibitor-69 (compound Test set 1) is a HIV-1 RT inhibitor .
|
-
- HY-146308
-
|
HIV
|
Infection
|
HIV-1 inhibitor-26 (compound 9a) is a potent HIV-1 reverse transcriptase (RT) inhibitor with an IC50 value of 1.4 μM. HIV-1 inhibitor-26 has low cytotoxicity with a CC50 of 1486 μM in PBMCs. HIV-1 inhibitor-26 can be used for researching AIDS .
|
-
- HY-150759
-
|
HIV
|
Infection
|
HIV-1 inhibitor-45 (compound IA-6) is a potent HIV-1 RNase H inhibitor with an IC50 value of 0.067 μM. HIV-1 inhibitor-45 shows an antiviral activity .
|
-
- HY-144715
-
|
HIV
|
Infection
|
HIV-1 inhibitor-18 (compound V-25i) is a potent HIV-1 capsid inhibitor with an EC50 value of 2.57 μM for HIV-1 NL4-3. HIV-1 inhibitor-18 has certain cytotoxicity (MT-4 cells CC50 >8.55) .
|
-
- HY-144714
-
|
HIV
|
Infection
|
HIV-1 inhibitor-18 (compound II-13c) is a potent HIV-1 capsid inhibitor with an EC50 value of 5.14 μM for HIV-1 NL4-3. HIV-1 inhibitor-18 has certain cytotoxicity (MT-4 cells CC50 >9.51) .
|
-
- HY-172093
-
|
HIV
|
Infection
|
HIV-1 inhibitor-80 (compound M44) is an HIV-1 inhibitor with an EC50 of 5-148 nM. HIV-1 inhibitor-80 shows good metabolic stability and cytotoxicity in human plasma and human liver microsomes .
|
-
- HY-146339
-
|
HIV
|
Infection
Inflammation/Immunology
|
HIV-1 inhibitor-27 (compound 5) is a potent HIV-1 inhibitor with IC50s of 16 μM, 0.5 μM and 0.39 μM for HIV-1 YU2, NL4-3 and 89.6 strain, respectively. HIV-1 inhibitor-27 has low cytotoxicity with a CC50 of 128 μM in TZM-bl cells. HIV-1 inhibitor-27 can be used for researching AIDS .
|
-
- HY-146017
-
|
HIV
|
Infection
|
HIV-1 inhibitor-22 (compound 11a) is a potent HIV-1 non-nucleoside reverse transcriptase (RT) inhibitor, with an IC50 value of 3.63 μM for HIV-1 RT. HIV-1 inhibitor-22 has antiretroviral activity against HIV-1 WT and K103N strains with EC50s of 0.304 μM and 0.201 μM, also has low cytotoxicity (CC50 > 227 μM)
|
-
- HY-144123
-
|
HIV
|
Infection
|
HIV-1 inhibitor-16 (compound 7a) is a highly potent HIV-1 inhibitor with an EC50 value of 1.3 nM for HIV-1 WT. HIV-1 inhibitor-16 also has certain inhibitory activity against HIV-1 K103N, E138K, Y181C and L100I strains with EC50s of 5.4 nM, 9.2 nM, 22 nM and 35 nM. HIV-1 inhibitor-16 has favorable solubility and liver microsome stability, and does not exhibit apparent CYP enzymatic inhibitory activity or acute toxicity .
|
-
- HY-169920
-
|
HIV
Reverse Transcriptase
|
Infection
|
HIV-1 inhibitor-79 (Compound 3k) is an HIV inhibitor that exhibits significant inhibitory activity against HIV-1 and its common mutant strains (with IC50 values of 1.9, 1.9, 8.7, and 11 nM against HIV-1, K103, L100I, and E138K, respectively), and has low cytotoxicity and a high selectivity index (CC50 = 21.95 μM, SI = 11478). Additionally, HIV-1 inhibitor-79 also shows antiviral activity against HIV-2, with an EC50 value of 6.14 μM, and significantly inhibits the activity of HIV-1 reverse transcriptase (IC50 = 25 nM) .
|
-
- HY-147370
-
|
HIV
|
Infection
|
HIV-1 inhibitor-46 (compound 13d) is a potent HIV-1 non-nucleoside reverse transcriptase inhibitor with an EC50 value of 1.425 μM. HIV-1 inhibitor-46 can be used for the research of AIDS .
|
-
- HY-162461
-
|
Reverse Transcriptase
HIV
|
Infection
|
HIV-1 inhibitor-66 is an orally active non-nucleoside reverse transcription inhibitor (NNRTI). HIV-1 inhibitor-66 shows inhibitory activity against wild-type HIV-1 reverse transcriptase with an IC50 of 40 nM .
|
-
- HY-147841
-
|
HIV
Reverse Transcriptase
|
Infection
|
HIV-1 inhibitor-41 (Compound B23) is an orally active non-nucleoside HIV-1 reverse transcriptase inhibitor with EC50 values of 20.8 nM and 50 nM against HIV-1 WT and mutant E138K strain, respectively. HIV-1 inhibitor-41 shows low hERG, no apparent CYP enzymatic inhibition and no acute toxicity .
|
-
- HY-151933
-
|
HIV
Reverse Transcriptase
|
Infection
|
HIV-1 inhibitor-49 is an orally active HIV-1 inhibitor, is a HEPT analog. HIV-1 inhibitor-49 possesses great pharmacokinetics profiles and potent non-nucleoside reverse transcriptase inhibitory activity (IC50=30 nM). HIV-1 inhibitor-49 exerts potential safety without acute toxicity in mouse model .
|
-
- HY-152160
-
|
HIV
Reverse Transcriptase
|
Infection
|
HIV-1 invistor-50 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that targets HIV-1 reverse transcriptase (RT) (IC50=50 nM). HIV-1 inhibitor-50 shows significant antiviral activity, with EC50s of 2.22-53.3nM against HIV-1 IIIB and its mutant strains .
|
-
- HY-155114
-
|
HIV
|
Infection
|
HIV-1 inhibitor-59 (Compound I-5b) is a HIV-1 inhibitor, with EC50s of 5.62-171 nM against the wild-type (WT) and mutant HIV-1 strains. HIV-1 inhibitor-59 has moderate RT enzyme inhibitory activity (IC50: 0.094-12.0 μM) .
|
-
- HY-169166
-
|
HIV Protease
|
Infection
|
HIV-1 protease-IN-14 (compound 5ae) is a potent HIV-1 protease inhibitor with Ki values of 0.28, 56.9 nM for WT HIV-1 PR, R41T HIV-1 PR, respectively. HIV-1 protease-IN-14 shows low cytotoxicity .
|
-
- HY-149936
-
|
HIV Protease
|
Infection
|
HIV-1 protease-IN-8 (compound 34b) is a potent HIV-1 protease inhibitor with an IC50 value of 0.32 nM. HIV-1 protease-IN-8 displays IC50s of 0.29 μM and 1.90 μM for wild-type HIV-1 (HIV-1NL4-3) and drug-resistant variant (HIV-1MDR), respectively. HIV-1 protease-IN-8 displays robust antiviral activity against both wild-type HIV-1 and drug-resistant variant .
|
-
- HY-146019
-
|
HIV
|
Infection
|
HIV-1 inhibitor-24 (compound S-12a) is a highly potent HIV-1 reverse transcriptase, with an IC50 value of 9.5 nM. HIV-1 inhibitor-24 has high antiretroviral activity against WT HIV-1 with an EC50 of 1.6 nM, and exhibits relatively low cytotoxicity with a CC50 of 9.07 μM in MT-4 cells. HIV-1 inhibitor-24 is well tolerated at a dose of 2 g/kg in mice and has a significant cardiovascular safety .
|
-
- HY-146353
-
|
HIV
|
Infection
Inflammation/Immunology
|
HIV-1 inhibitor-29 (compound 14d2) is a potent HIV-1 inhibitor with an EC50 of 2.18 μM for HIV-1 IIIB. HIV-1 inhibitor-29 has high anti-resistance profile toward F227L/V106A strain (EC50 = 0.974 μM), and exhibits low cytotoxicity in MT-4 cells (CC50 = 211 μM). HIV-1 inhibitor-29 can be used for researching AIDS .
|
-
- HY-146015
-
|
HIV
|
Infection
|
HIV-1 inhibitor-21 (compound 9b) is a potent HIV-1 non-nucleoside reverse transcriptase (RT) inhibitor, with an IC50 value of 0.55 μM for HIV-1 RT. HIV-1 inhibitor-21 has antiretroviral activity against HIV-1 WT and K103N strains with EC50s of 12.7 nM and 10.4 nM, and has relatively low cytotoxicity (MT-4 cells CC50 =10.2 μM) .
|
-
- HY-144122
-
|
HIV
|
Infection
|
HIV-1 inhibitor-15 (compound 9d) is a highly potent and broad-spectrum HIV-1 inhibitor. HIV-1 inhibitor-15 has inhibitory activity against HIV-1 WT, L100I, K103N, Y181C, E138K with EC50s of 1.7 nM, 4 nM, 2 nM, 6 nM and 9 nM, respectively. HIV-1 inhibitor-15 has good solubility, safety profiles and favorable oral bioavailability .
|
-
- HY-146019A
-
|
HIV
|
Infection
|
HIV-1 inhibitor-25 (compound R-12a) is a highly potent HIV-1 reverse transcriptase, with an IC50 value of 0.1061 μM. HIV-1 inhibitor-25 has high antiretroviral activity against WT HIV-1 with an EC50 of 13.6 nM, and exhibits relatively low cytotoxicity with a CC50 of 33.13 μM in MT-4 cells. HIV-1 inhibitor-25 also has inhibitory activity against HIV-1 mutant strains (L100I, K103N, Y181C, Y188L, E138K, F227L+V106A) with EC50 of 0.1961 ~ 5.8136 μM. HIV-1 inhibitor-25 can be used for researching AIDS .
|
-
- HY-146888
-
|
HIV Protease
|
Infection
|
HIV-1 protease-IN-2 is a potent HIV-1 protease inhibitor with an IC50 of 2.53 nM. HIV-1 protease-IN-2 shows antiviral activity against DRV (Darunavir)-sensitive or DRV-resistant HIV-1 variants .
|
-
- HY-147650
-
|
HIV Protease
|
Infection
|
HIV-1 protease-IN-5 (Compound 13c) is a HIV-1 protease inhibitor with an IC50 of 1.64 nM. HIV-1 protease-IN-5 shows remarkable activity against wild-type and DRV-resistant HIV-1 variants .
|
-
- HY-150599
-
|
HIV
DNA/RNA Synthesis
|
Infection
|
HIV-1 inhibitor-43 is a potent HIV-1 inhibitor with an EC50 of 21.3 nM, 6.2 nM, < 0.7 nM and < 0.7 nM for Y188L, K103N-Y181C, K103N and Y181C, respectively. HIV-1 inhibitor-43 can reduce HIV-1 RNA and protein p24 expression .
|
-
- HY-144688
-
|
HIV
|
Infection
|
HIV-1 protease-IN-1 (Compound 1e) is a potent inhibitor of HIV-1 protease with an IC50 of 90 pM. HIV-1 protease-IN-1 demonstrates antiviral activity with EC50 value of 89 nM against B-HIV. HIV-1 protease-IN-1 exhibits activity with EC50 value of 13.59 nM against C-HIV strain ZM246. HIV-1 protease-IN-1 shows remarkable activity with EC50 value of 8.23 nM against C-HIV strain Indie [1].
|
-
- HY-161270
-
|
HIV Protease
|
Infection
|
HIV-1 protease-IN-13 (compound 18d) is a potent HIV-1 protease inhibitor with an IC50 value of 0.54 nM. HIV-1 protease-IN-13 also shows potent activity against HIV-1DRVRS (DRV-resistant mutation) and HIV-1NL4_3 variant (wild type) .
|
-
- HY-142467
-
|
HIV
|
Infection
|
HIV-1 inhibitor-11, a fused pyridine ring derivative, is a HIV-1 inhibitor. WO2021104413A1 ( compound 1-1b) .
|
-
- HY-146753
-
|
HIV
|
Infection
|
HIV-1 inhibitor-20 is a potent HIV-1 inhibitor by non-classical isosteric replacement of amide to 1,2,4-oxadiazoles .
|
-
- HY-162253
-
|
HIV
|
Infection
|
HIV-1 inhibitor-64 (Compound 7c) is a wild-type HIV-1 inhibitor that effectively suppresses the activity of HIV-1 mutants E138K/Q148K and G140S/Q148R with EC50 values of 62.5 nM and 11.3 nM, respectively. HIV-1 inhibitor-64 exhibits antiviral activity and can be used in the research of AIDS .
|
-
- HY-169064
-
|
HIV
Reverse Transcriptase
|
Infection
|
HIV-1 inhibitor-75 is a human immunodeficiency virus 1 (HIV-1) inhibitor, with an EC50 value ranging from 0.0039 to 0.338 μM. The binding target of HIV-1 inhibitor-75 is reverse transcriptase, with an IC50 value of 0.055 μM. HIV-1 inhibitor-75 shows good in vitro metabolic stability, exhibiting moderate clearance rates and a longer half-life in human plasma and liver microsomes .
|
-
- HY-139631
-
|
HIV
|
Infection
|
HIV-1 inhibitor-9 is found to be potent inhibitor against the wild-type (WT) HIV-1 strain or multiple NNRTI-resistant strains at low nanomolar levels.
|
-
- HY-159150
-
|
HIV
|
Infection
|
HIV-1 inhibitor-71 (compound 2a) blocks the transport of endocytosed HIV-1 particles into nuclear envelope invagination (NEIs) that can inhibit productive infection .
|
-
- HY-128722
-
|
HIV
|
Infection
|
HIV-1 inhibitor-3 is a HIV infection inhibitor extracted from patent US2018360927 .
|
-
- HY-108255
-
|
HIV
|
Infection
|
HIV-1 inhibitor-60 (compound 45) is an HIV inhibitor with the potential for the research of infection diseases .
|
-
- HY-111079
-
|
HIV
Reverse Transcriptase
|
Others
|
HIV-1 inhibitor-70 (compound 20) is a bifunctional inhibitor that inhibits both wild-type (WT) and K103N mutant reverse transcriptases (RTs) of HIV-1.
|
-
- HY-155691
-
|
HIV Protease
|
Infection
|
HIV-1 protease-IN-12 (compound 35b) is a HIV-1 protease inhibitor with an IC50 of 0.51 nM. HIV-1 protease-IN-12 also inhibits drug-resistant variant .
|
-
- HY-156330
-
|
HIV
Cytochrome P450
|
Infection
|
HIV-IN-9 (Compound 2b) is a HIV inhibitor (IC50: 6.65 μg/mL), and has high binding affinity with HIV-RT. HIV-IN-9 also inhibits CYP3A4, CYP1A2, CYP2C1, and CYP2D6 .
|
-
- HY-155076
-
|
HIV Protease
|
Infection
|
HIV-1 protease-IN-9 (compound 5b) is a HIV-1 protease inhibitor, with a Ki of 0.028 nM. HIV-1 protease-IN-9 shows potent antiviral activity, with an IC50 of 66.8 nM .
|
-
- HY-148042
-
|
HIV
|
Infection
|
HIV-1 inhibitor-47 is an inhibitor of HIV-1, and inhibits vif-dependent degradation of human APOBEC3G, with an IC50 value of 14.33 μM. HIV-1 inhibitor-47 also involves in derivatives of 1-(2-pyrimidinyl)piperazine synthesis, with potential antianxiety, antidepressant, and antipsychotic effect .
|
-
- HY-155690
-
|
HIV Protease
|
Infection
|
HIV-1 protease-IN-11 (compound 34a) is a HIV-1 protease inhibitor with an IC50 of 0.41 nM. HIV-1 protease-IN-11 also exhibits significant activity against drug-resistant variant .
|
-
- HY-10891
-
-
- HY-152161
-
|
HIV
Reverse Transcriptase
|
Infection
|
HIV-1 inhibitor-51, a non-nucleoside reverse transcriptase inhibitor (NNRTI), exhibits outstanding antiviral activity against WT HIV-1 (IIIB) and a panel of mutant strains. HIV-1 inhibitor-51 has high binding affinity (KD=2.50 μM) and inhibitory activity (IC50=0.03 μM) to WT HIV-1 RT. HIV-1 inhibitor-51 has EC50s of 2.22-53.3 nM for mutant strains (L100I, K103N, Y181C, Y188L, E138K, F227L + V106A, RES056) .
|
-
- HY-155599
-
|
HIV
PKC
|
Infection
|
HIV-1 protease-IN-10 (Compound 2) has HIV-1 latency reversing activity (IC50: 0.22 μM). HIV-1 protease-IN-10 binds to the PKCδ C1b domain (IC50: 0.69 μM). HIV-1 protease-IN-10 has stability against esterase-mediated hydrolysis .
|
-
- HY-146012
-
|
HIV
|
Infection
|
HIV-1 protease-IN-4 (Compound II-22) is a potent HIV-1 protease inhibitor. HIV-1 protease-IN-4 is a proagent of atazanavir. HIV-1 protease-IN-4 as a proagent that delivers the parent 1 to rat plasma with a 5-fold higher AUC and 67-fold higher C24 when compared to oral administration of the parent agent .
|
-
- HY-146746
-
|
HIV
|
Infection
|
HIV-1 inhibitor-19 is a potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI). HIV-1 inhibitor-19 maintains its inhibitory activity against L100I, K103N and V106A/ F227L mutant strains with EC50s of 7.3 nM, 9.2 nM and 21.0 nM, respectively[1].
|
-
- HY-146365
-
|
HIV
|
Infection
Inflammation/Immunology
|
HIV-1 inhibitor-30 (compound 10i) is a potent HIV-1 inhibitor with an EC50 value of 40 nM and an IC50 value of 80 nM for HIV-1 RT DNA polymerase. HIV-1 inhibitor-30 has highly antiretroviral activity against seven non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1 strains (RT-K103N; RT-Y181C; RT-K103N,Y181C; RT-L100I,K103N; RT-Y188L; RT-K103N,G190A; RT-K103N,V108I) with IC50s of 0.04~1.42 μM. HIV-1 inhibitor-30 can be used for researching AIDS .
|
-
- HY-138562
-
|
HIV
|
Infection
|
HIV-1 Nef-IN-1 is an HIV-1 Nef protein inhibitor that efficiently competes for Nef-SH3Hck interactions with a Kd of 6.7 μM .
|
-
- HY-151250
-
|
HIV Protease
|
Infection
|
HIV-1 protease-IN-7 (compound 16) is an orally active HIV-1 protease inhibitor (IC50=3.52 nM, EC50=37 nM) .
|
-
- HY-146804
-
|
HIV
HIV Protease
|
Infection
|
HIV-1 protease-IN-3 (compound 14) is a potent inhibitor of HIV-1 protease (IC50=71 nM; EC50=0.86 μM) .
|
-
- HY-162526
-
|
HIV
|
Infection
|
HIV capsid modulator 2 (Compound 7t) is a modulator for the HIV capsid (CA) protein. HIV capsid modulator 2 exhibits antiviral activity, which inhibits HIV-1 IIIB strain and HIV-2 ROD strain with EC50 of 0.04 and 0.13 μM. HIV capsid modulator 2 is metabolically stable in human liver microsomes .
|
-
- HY-161924
-
|
HIV
|
Infection
|
HIV-1 inhibitor-73 (compound 13c) is a potent anti-HIV-1 agent, against the whole tested viral panel with EC50 ranging from 4.68 to 229 nM .
|
-
- HY-159091
-
|
HIV Integrase
|
Infection
|
HIV-1 integrase inhibitor 12 (Compound 17) is an inhibitor for HIV-1 integrase with an IC50 of 1.4 nM. HIV-1 integrase inhibitor 12 inhibits the HIV-1 WT and HIV-1 T125A, with IC50 of 7.4 and 120 nM, respectively. HIV-1 integrase inhibitor 12 exhibits metabolic stability and Caco-2 permeability, and good pharmacokinetic characteristics with good bioavailability (64%) and low clearance (0.16 L/hr/kg) in rats .
|
-
- HY-150079
-
|
HIV Integrase
|
Infection
|
HIV-1 integrase inhibitor 10 is an orally active HIV-1 allosteric integrase inhibitor (ALLINI). HIV-1 integrase inhibitor 10 can inhibit viral outgrowth of the NLRepRluc virus in MT-2 cells with EC50 values of 3-5 nM. HIV-1 integrase inhibitor 10 can be used for the research of Human immunodeficiency virus-1 (HIV-1) .
|
-
- HY-146204
-
|
HIV
|
Infection
|
HIV-1 capsid inhibitor 1 is a potent HIV-1 Capsid inhibitor with an EC50 value of 3.13 µM. HIV-1 capsid inhibitor 1 shows antiviral activities .
|
-
- HY-P1491
-
|
HIV
|
Infection
|
HIV-1 TAT (48-60) is a cell-penetrating peptide derived from the human immunodeficient virus (HIV)-1 Tat protein residue 48-60. It has been used to deliver exogenous macromolecules into cells in a non-disruptive way.
|
-
- HY-107485
-
-
- HY-110253
-
HIV-1 inhibitor 18A
|
HIV
|
Infection
|
18A (HIV-1 inhibitor 18A) is a reversible broad-spectrum HIV-1 inhibitor. 18A exhibits broad inhibitory activity against multiple HIV-1 strains by blocking the function of Env .
|
-
- HY-132572
-
|
HIV
|
Infection
|
HIV-1 integrase inhibitor 9 (compound 8a) is a potent HIV-1 RNase H inhibitor with an IC50 of 12.3 μM. HIV-1 integrase inhibitor 9 shows an antiviral activity .
|
-
- HY-130760
-
|
HIV Integrase
|
Infection
|
HIV-1 integrase inhibitor 7 is a potent HIV-1 integrase inhibitor, with an IC50 of 33.3 nM .
|
-
- HY-P10251
-
|
HIV
|
Infection
|
HIV gp120 (318-327) is a short sequence of the HIV-1 strain IIIB envelope peptide (rgpgrafvti) that corresponds to the conserved C-terminal region of the glycoprotein. HIV gp120 (318-327) is part of the HIV vaccine V3 peptide epitope, also known as the I10 peptide. However, HIV gp120 (318-327) lacks the A2 anchor residues recognized by epitope-specific CTLs but has structural features that confer promiscuous A2 binding .
|
-
- HY-108817
-
|
HIV Integrase
HIV
|
Infection
|
HIV-1 integrase inhibitor 3 is a HIV-1 integrase strand transfer (INST) inhibitor with an IC50 of 2.7 nM.
|
-
- HY-108820
-
|
HIV Integrase
HIV
|
Infection
|
HIV-1 integrase inhibitor 4 is a HIV-1 integrase strand transfer (INST) inhibitor with an IC50 of 3.7 nM.
|
-
- HY-W507252
-
|
HIV Integrase
|
Infection
|
HIV-1 integrase inhibitor 11 (compound 5) is a potent inhibitor of HIV-1 integrase, with the IC50 of 125 μM .
|
-
- HY-151197
-
|
HIV Protease
|
Infection
|
HIV protease-IN-1 (compound 1·succinate) is a potent HIV protease non-peptidic inhibitor, can be used to research AIDS .
|
-
- HY-P1885
-
|
HIV
|
Infection
|
HIV gag peptide (197-205) is a H-2K d-restricted epitope derived from the p24 portion of the HIV-1 gag protein, consists of amino acids 197-205 (AMQMLKETI) .
|
-
- HY-P4352
-
|
HIV
|
Others
|
HIV-2 Peptide is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
|
-
- HY-P1757
-
|
HIV
|
Infection
|
HIV p17 Gag (77-85) is an HLA-A*0201(A2)-restricted CTL epitope, used in the research of anti-HIV .
|
-
- HY-13025
-
|
HIV
HIV Integrase
|
Infection
|
HIV-1 integrase inhibitor is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-P4351
-
|
HIV
|
Others
|
HIV-1 gag Protein p24 (194-210) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
|
-
- HY-149491
-
|
TAM Receptor
HIF/HIF Prolyl-Hydroxylase
|
Others
|
Axl-IN-16 (Compound 4) is a Axl inhibitor. Axl-IN-16 inhibits Axl expression and inhibits the activity of HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 can be isolated from“fruiting liquid (FL)” of Hypholoma lateritium and Hericium erinaceus .
|
-
- HY-P4055
-
-
- HY-P3951
-
-
- HY-P1566
-
|
HIV
|
Infection
|
MPG, HIV related is 27-aa peptide, derived from both the nuclear localisation sequence of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41 and is a potent delivery agent for the generalised delivery of nucleic acids and of oligonucleotides into cultured cells.
|
-
- HY-125712
-
|
HIV
HIV Protease
|
Infection
|
CGP 53820 is an inhibitor for HIV protease, inhibits the complex of HIV-1 and HIV-2 protease with Ki of 9 and 53 nM for HIV-1 protease and HIV-2 protease. CGP 53820 can be used in AIDS research .
|
-
- HY-105249
-
|
HIV
Reverse Transcriptase
|
Infection
|
RDEA 806 is an orally active non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits potent in vitro inhibitory activity against both wild-type HIV-1 (EC50 = 3.05 nM) and NNRTI-resistant HIV-1 .
|
-
- HY-164675
-
|
HIV
|
Infection
|
gp120-IN-3 (Compound 11) is a HIV-1 gp120 inhibitor with an IC50 value of 1.64 nM, which can be utilized in HIV research .
|
-
- HY-P5503
-
|
HIV
|
Others
|
Pol (476-484), HIV-1 RT Epitope is a biological active peptide. (This is a reverse transcriptase (RT) epitope (Pol residues 476-484). Within HIV-1 RT the peptide appears to be the dominant HLA A*0201-restricted epitope. Was used to investigate possible mechanisms behind HIV-1 escape from CTL. IV9 is the actual epitope processed and presented in HIV-1-infected cell lines.)
|
-
- HY-106188
-
|
HIV Protease
|
Infection
|
L 756423 is a potent HIV protease inhibitor. L 756423 has the potential for the research of HIV infection .
|
-
- HY-P10834
-
|
HIV
|
Infection
|
NYAD-13 exhibits antiviral activity against HIV-1 IIIB, but it also possesses significant cytotoxicity.
|
-
- HY-169291
-
|
HIV
|
Infection
|
Antiviral agent 62 (Compound 16 h) is an orally active antiviral agent that inhibits the activity of HIV with an IC50 value of 8 nM against HIV (MJ4) .
|
-
- HY-153005
-
|
HIV
|
Infection
|
(2RS)-FPMPA can be used for synthesis of antiretroviral agents against HIV-1 and HIV-2 .
|
-
- HY-153247
-
-
- HY-121611
-
|
HIV
|
Inflammation/Immunology
|
HI-236 is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase.?
HI-236 inhibits HIV activity (wild type HTLVIIB IC50p24 < 0.001 μM) .
|
-
- HY-P1801
-
Cys-[HIV-Tat (47-57)]
|
HIV
|
Infection
|
Cys-TAT(47-57) (Cys-[HIV-Tat (47-57)]) is an arginine rich cell penetrating peptide derived from the HIV-1 transactivating protein.
|
-
- HY-P990874
-
|
HIV
|
Infection
|
Anti-HIV gp120 Antibody (55-36) is a kind of mouse IgG1κ chimeric antibody, targeting to HIV gp120. The recommend isotype control of Anti-HIV gp120 Antibody (55-36): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-105216
-
-
- HY-P10517A
-
SFT acetate
|
HIV
|
Infection
|
Sifuvirtide (SFT) acetate is a potent HIV fusion inhibitor. Sifuvirtide acetate inhibits HIV-1 mediated cell fusion in a dose-dependent manner and is highly potent against infection by primary and laboratory-adapted HIV-1 isolates of multiple genotypes. Sifuvirtide acetate can be used in the research of anti-HIV drugs .
|
-
- HY-10570S
-
-
- HY-120880
-
-
- HY-122453
-
|
HIV Protease
|
Infection
|
Palinavir is a potent human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) protease inhibitor with an IC50 of 0.5-30 nM . Palinavir has antiviral activity .
|
-
- HY-163851
-
|
PROTACs
HIV
|
Infection
|
PROTAC Vif degrader-1 (Compound L15) is a Vif PROTAC degrader. PROTAC Vif degrader-1 has antiviral activity against HIV-1 (EC50: 33.35 μM against HIV-1IIIB). Blue: CRBN ligand (HY-10984); Black: linker; Pink: HIV-1 inhibitor(HY-163852) .
|
-
- HY-P1801A
-
Cys-[HIV-Tat (47-57)] TFA
|
HIV
|
Infection
|
Cys-TAT(47-57) (Cys-[HIV-Tat (47-57)]) is an arginine rich cell penetrating peptide derived from the HIV-1 transactivating protein.
|
-
- HY-118740
-
|
HIV
|
Infection
|
L-708906 is a potent human immunodeficiency virus type 1 (HIV-1) inhibitor with an IC50 value of 12 μM. L-708906 inhibits HIV strains resistant to nonnucleoside or nucleoside reverse transcriptase inhibitors .
|
-
- HY-103078A
-
|
HIV
|
Infection
|
I-XW-053 is an inhibitor of HIV-1 capsid protein that can suppress the replication of HIV-189BZ167 with an IC50 value of 164.2 μM. I-XW-053 exhibits antiviral activity and can block the interface between capsid protein (CA) N-terminal domains (NTD-NTD interface) with micromolar affinity .
|
-
- HY-103078
-
|
HIV
|
Infection
|
I-XW-053 is an inhibitor of HIV-1 capsid protein that can suppress the replication of HIV-189BZ167 with an IC50 value of 164.2 μM. I-XW-053 exhibits antiviral activity and can block the interface between capsid protein (CA) N-terminal domains (NTD-NTD interface) with micromolar affinity .
|
-
- HY-P10517
-
SFT
|
HIV
|
Infection
|
Sifuvirtide (SFT) is a potent HIV fusion inhibitor. Sifuvirtide inhibits HIV-1 mediated cell fusion in a dose-dependent manner and is highly potent against infection by primary and laboratory-adapted HIV-1 isolates of multiple genotypes. Sifuvirtide can be used in the research of anti-HIV drugs .
|
-
- HY-P2493
-
|
HIV
|
Others
|
(Cys47)-HIV-1 tat Protein (47-57) has membrane translocation function and can be used to derivatize the surface of magnetic pharmaceuticals and substantially facilitated their uptake into target cells .
|
-
- HY-118747
-
|
HIV
|
Infection
|
Scirpusin A is a naturally occurring compound extracted from the legume plant Caragana rosea Turcz, exhibiting anti-HIV activity. Scirpusin A demonstrates significant inhibitory effects against HIV-1 (EC50=7 μg/mL). Scirpusin A is utilized in research towards the development of anti-HIV therapeutics .
|
-
- HY-127078
-
|
HIV
|
Others
|
Salaspermic acid is a new triterpene acid isolated from Salacia macrosperma Wight. Salaspermic acid is an inhibitor of HIV reverse transcriptase and HIV replication in H9 lymphocyte cells .
|
-
- HY-125148
-
|
HIV Protease
|
Infection
|
AQ148 is a HIV-1 protease inhibitor (Ki=137 nM). The IC50 values ??of AQ148 for the inhibition of HIV-1, HIV-2 and SIV aspartic proteases are 1.5 μM, 3.4 μM and 5 μM, respectively .
|
-
- HY-106920
-
KNI 272; Kynostatin; NSC 651714
|
HIV Protease
|
Infection
|
Kynostatin 272 (KNI 272) is a potent HIV protease inhibitor. Kynostatin 272 inhibits the activity of the HIV protease by simulating the substrate transition state of the HIV protease, thus preventing a key step in the replication of the HIV virus. Kynostatin 272 provides an important research foundation for the development of drugs for HIV and AIDS .
|
-
- HY-14891
-
GSK2248761; FDV
|
HIV
Reverse Transcriptase
|
Infection
|
Fosdevirine (GSK2248761) is is a potent, selective, non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1) replication with low nanomolar activity in vitro. Fosdevirine shows good activity against a broad range of HIV-1 strains, including efavirenz (HY-10572)-resistant clinical isolates .
|
-
- HY-P0281A
-
|
HIV
|
Infection
|
TAT TFA (YGRKKRRQRRR) is derived from the transactivator of transcription (TAT) of human immunodeficiency virus (HIV-1) and is a cell-penetrating peptide. TAT can increase the yields and the solubility of heterologous proteins .
|
-
- HY-P0281
-
|
HIV
|
Infection
|
TAT (YGRKKRRQRRR) is derived from the transactivator of transcription (TAT) of human immunodeficiency virus-1 (HIV-1) and is a cell-penetrating peptide. TAT can increase the yields and the solubility of heterologous proteins .
|
-
- HY-W718146
-
|
HIV
|
Others
|
Tremuloidin (Compound 2) is a salicylic acid derivative derived from Homalium cochinchinensis. Tremuloidin has a weak activity against HIV-1 .
|
-
- HY-161945
-
|
HIV
HIV Integrase
|
Infection
|
IN-RNA-IN-2 (compound 1a) is an inhibitor (IC50=70 nM) of the interaction between HIV-1 integrase and the viral RNA genome. IN-RNA-IN-2 exerts its anti-HIV activity by inhibiting the viral replication process .
|
-
- HY-158128
-
|
HIV
Reverse Transcriptase
|
Infection
|
MK-8527 is an HIV inhibitor and nucleoside reverse transcriptase translocation inhibitor (NRTTI). MK-8527 has a similar inhibitory mechanism to ISL (HY-104012) .
|
-
- HY-P4292
-
|
HIV
Amino Acid Derivatives
|
Infection
|
H-Gly-Pro-Gly-NH2 is a tripeptide that inhibits HIV-1 replication. H-Gly-Pro-Gly-NH2 inhibits the activity of HIV-1 IIIB and HIV-2 ROD with EC50 values of 35 µM and 30 µM, respectively. H-Gly Pro Gly NH2 inhibits HIV-1 replication in vitro by interfering with capsid formation. H-Gly Pro Gly NH2 has antiviral activity and can be used for virus research .
|
-
- HY-123608
-
|
HIV Protease
|
Infection
|
JE-2178 is an orally available HIV-1 protease inhibitor with IC50 and Ki values are 15 and 0.318 nM respectively. JE-2178 has antiviral activity .
|
-
- HY-17040
-
TMC114; UIC-94017
|
HIV
HIV Protease
|
Infection
Inflammation/Immunology
|
Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC50 = 0.003 μM; IC90 = 0.009 μM) with minimal cytotoxicity .
|
-
- HY-W251687
-
-
- HY-14388
-
|
CCR
HIV
|
Infection
|
PF-232798 is an orally active CCR5 antagonist with anti-HIV effects .
|
-
- HY-136548
-
-
- HY-160267
-
-
- HY-136548A
-
TFV-DP triethylamine
|
Reverse Transcriptase
|
Infection
Inflammation/Immunology
|
Tenofovir diphosphate triethylamine (TFV-DP triethylamine) is a competitive DNA polymerases inhibitor (with respect to dATP) and a substrate of HIV type 1 (HIV-1) reverse transcriptase (RT) .
|
-
- HY-162074
-
|
HIV
|
Infection
|
Nipamovir is a nitroimidazole prodrug. Nipamovir shows comparable antiviral activity to SAMT-247 (HY-102077) and NS-1040 in both cellular assays and a human ex vivo model of HIV infection, along with low toxicity. Nipamovir has EC50 values of 3.64±3.28 and 3.23±2.81 μM for CEM-SS/HIV-1RF and hPBMC/HIV-192HT599, respectively .
|
-
- HY-P4810
-
T140
|
CXCR
|
Infection
|
Polyphemusin II-Derived Peptide (T140), a CXCR4 inhibitor, shows high inhibitory activity against HIV-1 entry and the inhibitory effect on the binding of an anti-CXCR4 monoclonal antibody (12G5) to CXCR4 .
|
-
- HY-123896
-
|
HIV
|
Infection
|
Calceolarioside A is phenylethanoid glycoside with moderate binding affinity on HIV gp41 .
|
-
- HY-161047
-
|
HIV
|
Infection
|
Antiviral agent 45 (compound 9a) is an antiviral agent. Antiviral agent 45 inhibits HIV-1 andHIV-2 with IC50s of 35 and 3.1 nM, respectively .
|
-
- HY-P99564
-
-
- HY-120712
-
|
HIV Protease
|
Infection
|
Ro 31-8588 is a HIV protease inhibitor with the Ki of 0.3 nM. Ro 31-8588 can be used for study of AIDS .
|
-
- HY-107001
-
(S)-DPC 961; DMP 961
|
HIV
Reverse Transcriptase
|
Infection
|
DPC 961 (DMP 961) is a non-nucleoside reverse transcriptase inhibitor (NNRTI). DPC 961 is a potent and specific inhibitor of HIV-1 reverse transcriptase, which inhibits the activity of HIV-1 reverse transcriptase in a non-competitive manner, thereby preventing viral replication. DPC 961 can be used for research on AIDS .
|
-
- HY-19111
-
TIBO-R 82150
|
HIV
Reverse Transcriptase
|
Infection
|
R-82150 (TIBO-R 82150) is an HIV-1 reverse transcriptase inhibitor that blocks the reverse transcription of viral RNA by binding to the non-substrate binding site of reverse transcriptase, thereby inhibiting viral replication. R-82150 does not inhibit the replication of HIV-2, other RNA viruses, and DNA viruses .
|
-
- HY-105025A
-
Thymopoietin II (32-35) (TFA); TP 4 TFA
|
Apoptosis
|
Inflammation/Immunology
|
Thymocartin TFA is the TFA salt form of Thymocartin (HY-105025). Thymocartin TFA inhibits apoptosis of peripheral blood lymphocytes in HIV infected individuals. Thymocartin TFA is potential for immunodeficiency diseases research .
|
-
- HY-N11780
-
|
HIV
|
Infection
|
Clavirolide L (Compound 3) is a dolabellane-type diterpenoid that can be isolated from Clavularia viridis. Clavirolide L shows significant inhibition against HIV-1 without RT enzyme inhibition and can be used for HIV infection research .
|
-
- HY-P10427
-
|
CXCR
HIV
|
Infection
|
DV1 is a selective antagonist for CXC chemokine receptor 4 (CXCR4). DV1 exhibits antiviral activity by blocking HIV-1 entry through the CXCR4 co-receptor. DV1 is stable in rat plasma and exhibits good pharmacokinetic characteristics in rat models .
|
-
- HY-P99433
-
U 85855
|
HIV
|
Infection
|
Alvircept sudotox is a recombinant CD4 derived from Pneumonas aeruginosa exotoxin A. Alvircept sudotox can be used in the research of HIV infections .
|
-
- HY-N8368
-
|
HIV
|
Infection
|
Neotripterifordin is a inhibitor of HIV. Neotripterifordin has anti-HIV replication activity in H9 lymphocyte cells with an EC50 of 25 nM .
|
-
- HY-19232
-
|
HIV Protease
|
Inflammation/Immunology
|
R-87366 is a water-soluble human immunodeficiency virus (HIV) protease inhibitor. R-87366 has potent inhibitory for HIV protease with a Ki value of 11 nM. R-87366 can be used for the research of anti-human immunodeficiency virus (HIV) .
|
-
- HY-118423
-
IQP-0410
|
HIV
|
Inflammation/Immunology
|
SJ-3366 (IQP-0410) is a potent inhibitor of HIV nonnucleoside reverse transcriptase . SJ-3366 (IQP-0410) inhibits HIV at sub-nanomolar concentrations primarily through a typical non-nucleoside mechanism .
|
-
- HY-120072
-
PF-74
|
HIV
|
Infection
|
PF-3450074 (PF-74) is a specifical inhibitor of?HIV-1 capsid protein (CA) and displays a broad-spectrum inhibition of HIV isolates with submicromolar potency (EC50=8-640 nM). PF-3450074 (PF-74) acts at an early stage of HIV-1 infection, inhibits viral replication by directly competing with the binding of CPSF6 and NUP153, and blocks the uncoating, assembly, and the reverse transcription steps of the viral life cycle . CPSF6: nuclear host factors cleavage and polyadenylation specific factor 6; NUP153: nucleoporin 153.
|
-
- HY-115430
-
-
- HY-N9340
-
|
HIV
|
Infection
|
Hypoglaunine D is an analogue of Triptonine B and acts as an anti-HIV compound. Hypoglaunine D inhibits HIV replication in H9 lymphocytes with an EC50 value of 22 μg/ml .
|
-
- HY-139158
-
|
HIV
|
Infection
|
Ainuovirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). Ainuovirine inhibits HIV replication by non-competitively binding to HIV reverse transcriptase and blocking the reverse transcription process of viral RNA. Ainuovirine can be used for human immunodeficiency virus (HIV) type 1 infection .
|
-
- HY-106282
-
|
HIV
|
Infection
|
BIT-225 is an inhibitor for Vpu protein through block of Vpu ion channel, and thus inhibits the release of HIV-1, especially in monocyte-derived macrophages (EC50 is 2.25 μM), without significant cytotoxicity (TC50 is 284 μM) .
|
-
- HY-147653
-
|
HIV Integrase
|
Infection
|
Integrase-LEDGF/p75 allosteric inhibitor 1 (Compound 31h) is an orally active integrase-LEDGF/p75 (IN-LEDGF/p75) allosteric inhibitor. Integrase-LEDGF/p75 allosteric inhibitor 1 inhibits HIV-1 DNA integration and shows antiviral activity with an EC50 of 3.9 nM against HIV-1 recombinant molecular clone NL432 .
|
-
- HY-106038
-
Dacopafant; RP 55778
|
HIV
Platelet-activating Factor Receptor (PAFR)
|
Infection
|
Acopafant (Dacopafant; RP 55778) is a potent platelet-activating factor antagonist. Acopafant inhibits the induction of human immunodeficiency virus (HIV) expression in chronically infected cells. Acopafant has the potential for the research of HIV infection .
|
-
- HY-108818
-
-
- HY-P10056
-
Human ezrin peptide (324-337)
|
HIV
|
Infection
|
HEP-1 (Human ezrin peptide (324-337)) is an orally active peptide with anti-HIV activity. HEP-1 enhances antibody titers generated by hepatitis B vaccination. HEP-1 has the potential to be studied against viral infections .
|
-
- HY-156599
-
|
HIV
|
Infection
|
Bavtavirine is a potent non-nucleoside reverse transcriptase inhibitors (NNRTIs). Bavtavirine is part of highly active antitiretroviral therapy (HAART) treatment regimen. Bavtavirine can be used for HIV disease research .
|
-
- HY-112393
-
|
HIV
Src
PKA
PKC
|
Infection
|
TX-1918 is an inhibitor for eukaryotic elongation factor 2 kinase (eEF2-K) and Src kinase with IC50 of 0.44 and 4.4 μM, respectively. TX-1918 exhibits cytotoxicity in cell HepG2 and HCT116, with IC50 of 2.07 and 230 μM, respectively. TX-1918 inhibits the C-terminal domain of HIV-1 CA (CA CTD)(IC50 =3.81 μM), and inhibits the viral replication (IC50 =15.16 μM) .
|
-
- HY-121291
-
|
HIV
|
Infection
|
Aureothin, is a natural polyketide, is a HIV inhibitor with an IC50 of 5.3 nM. Aureothin is a microbial biolarvicide .
|
-
- HY-157172
-
|
Integrin
|
Infection
Neurological Disease
|
MorHap is a heroin hapten. MorHap conjugated to tetanus toxoid (TT), palm-CV2, and to monophosphoryl lipid A (MPLA)-containing liposomes partially blocks heroin-induced analgesia and hyperlocomotion in mice. MorHap designed conjugates also significantly inhibits HIV-1 binding to α4β7 receptors. MorHap can be used in research to develop vaccines related to heroin addiction and HIV-1 infection .
|
-
- HY-19314A
-
RO-0622 hydrochloride; FNC hydrochloride
|
Reverse Transcriptase
HIV
HBV
HCV
|
Infection
|
Azvudine (RO-0622) hydrochloride is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV. Azvudine hydrochloride exerts highly potent inhibition on HIV-1 (EC50s ranging from 0.03 to 6.92 nM) and HIV-2 (EC50s ranging from 0.018 to 0.025 nM). Azvudine hydrochloride inhibits NRTI-resistant viral strains . Azvudine (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-19314
-
RO-0622; FNC
|
Reverse Transcriptase
HIV
HBV
HCV
|
Infection
|
Azvudine (RO-0622) is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV. Azvudine exerts highly potent inhibition on HIV-1 (EC50s ranging from 0.03 to 6.92 nM) and HIV-2 (EC50s ranging from 0.018 to 0.025 nM). Azvudine inhibits NRTI-resistant viral strains . Azvudine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-W749636
-
-
- HY-136548B
-
TFV-DP disodium
|
HIV
|
Infection
Inflammation/Immunology
|
Tenofovir diphosphate disodium is an antiretroviral agent and an inhibitor of DNA polymerases. Tenofovir diphosphate disodium is a substrate of HIV-1 reverse transcriptase (RT). Tenofovir diphosphate disodium can be used for the research of Aids .
|
-
- HY-N4100
-
|
TNF Receptor
HIV
SGLT
|
Infection
|
Trilobatin, a natural sweetener derived from Lithocarpus polystachyus Rehd , Trilobatin is an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope . Neuroprotective effects . Trilobatin is also a SGLT1/2 inhibitor that selectively induces the proliferation of human hepatoblastoma cells .
|
-
- HY-N3511
-
|
HIV
|
Infection
|
Triptonine B, a sesquiterpene pyridine alkaloid, inhibits HIV replication in H9 lymphocytes with an EC50 value of <0.10 μg/mL .
|
-
- HY-W787717
-
|
HIV
|
Infection
Inflammation/Immunology
Cancer
|
12-Methoxydodecanoic acid, a heteroatom-containing analog of myristic acid, possesses anti-viral activity against HIV, with an IC50 of 6.8 μM. 12-Methoxydodecanoic acid inhibits moloney murine leukemia virus (MoMLV) .
|
-
- HY-106958
-
HBY 097
|
HIV
Reverse Transcriptase
|
Infection
|
Talviraline is a non-nucleoside reverse transcriptase (NNRT) inhibitor that is primarily used to inhibit the replication of human immunodeficiency virus type 1 (HIV-1). Talviraline inhibits the viral replication process by binding to a specific site of HIV-1 reverse transcriptase (RT). Talviraline can be used to study the potential countermeasures and safety of HIV-1 infection .
|
-
- HY-126082
-
|
HIV
Reverse Transcriptase
|
Infection
|
(+)-Carbovir triphosphate is an enantiomer of Carbovir triphosphate (HY-131607). (+)-Carbovir triphosphate is an inhibitor and substrate of HIV reverse transcriptase .
|
-
- HY-122786
-
|
Antibiotic
HIV
|
Infection
|
3-O-Methylviridicatin is an indole alkaloid. 3-O-Methylviridicatin inhibits TNF-alpha induced HIV replication with an IC50 of 2.5 μM .
|
-
- HY-117477
-
|
Reverse Transcriptase
HIV
|
Infection
|
DPC-963 is an oral active non-nucleoside reverse transcriptase inhibitor with the IC50 of 18 nM. DPC-963 can be used for study of HIV .
|
-
- HY-150747
-
|
IFNAR
|
Inflammation/Immunology
|
ODN 6016 is a CpG-A oligonucleotides. ODN 6016 can induce IFN-α production, can be used for researching immune disorders including immunodeficiency caused by HIV-1. ODN 6016 sequence: T-sp-C-G-A-C-G-T-C-G-T-G-G-sp-G-sp-G-sp-G .
|
-
- HY-150747A
-
|
IFNAR
|
Inflammation/Immunology
|
ODN 6016 sodium is a CpG-A oligonucleotides. ODN 6016 sodium can induce IFN-α production, and can be used for researching immune disorders including immunodeficiency caused by HIV-1. ODN 6016 sequence: T-sp-C-G-A-C-G-T-C-G-T-G-G-sp-G-sp-G-sp-G .
|
-
- HY-P3554
-
|
HIV
|
Infection
|
Carbomethoxycarbonyl-D-Pro-D-Phe-OBzl (compound (CPF(LL)) is an HIV-1 inhibitor. Carbomethoxycarbonyl-D-Pro-D-Phe-OBzl interacts with gp120 to block gp120 binding to CD4 and preserve CD4-dependent T cell function .
|
-
- HY-131596
-
(-)-Emtricitabine triphosphate
|
HIV
|
Infection
|
Emtricitabine triphosphate ((-)-Emtricitabine triphosphate) is the phosphorylated anabolite of Emtricitabine (HY-17427). Emtricitabine is a nucleoside reverse transcriptase inhibitor. Emtricitabine is antiretroviral agent for HIV and HBV infection .
|
-
- HY-14231
-
|
CCR
|
Infection
Inflammation/Immunology
|
CCR5 antagonist 5 (compound example 11) is a CCR5 antagonist. CCR5 antagonist 5 has the potential to study inflammation and immunity and viral (such as HIV) infection .
|
-
- HY-P9998
-
UB421
|
HIV
|
Cancer
|
Semzuvolimab is a murine IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Murine CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection .
|
-
- HY-P10076
-
L-HIV-TAT(48–57)-PP-JBD20
|
JNK
|
Metabolic Disease
|
TAT-JBD20 (L-HIV-TAT(48–57)-PP-JBD20) is a JNK peptide inhibitor. TAT-JBD20 can be used for research of diabetes .
|
-
- HY-N4100R
-
|
TNF Receptor
HIV
SGLT
|
Infection
|
Trilobatin (Standard) is the analytical standard of Trilobatin. This product is intended for research and analytical applications. Trilobatin, a natural sweetener derived from?Lithocarpus polystachyus?Rehd , Trilobatin?is an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope . Neuroprotective effects . Trilobatin is also a SGLT1/2 inhibitor that selectively induces the proliferation of human hepatoblastoma cells .
|
-
- HY-10493
-
GS-9350
|
Cytochrome P450
HIV
|
Infection
Cancer
|
Cobicistat is a potent and selective inhibitor of cytochrome P450 3A (CYP3A) enzymes with IC50s of 30-285 nM. Cobicistat is a pharmacokinetic enhancer which increases the overall absorption of several HIV medications.
|
-
- HY-16658C
-
Z-VA-DL-D(OH)-FMK
|
Caspase
|
Infection
|
Z-VA-DL-D-FMK (Z-VA-DL-D(OH)-FMK) is an inhibitor for caspase . Z-VA-DL-D-FMK binds irreversibly to caspases, increases the sensitivity of TNF-α, and activates HIV replication in infected T cell ACH-2 .
|
-
- HY-P1065A
-
|
HIV
Apelin Receptor (APJ)
|
Infection
Cardiovascular Disease
Metabolic Disease
|
Apelin-36(rat, mouse) TFA is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-36(rat, mouse) TFA binds to APJ receptors with an IC50 of 5.4 nM, and potently inhibits cAMP production with an EC50 of 0.52 nM. Apelin-36(rat, mouse) TFA blocks entry of some HIV-1 and HIV-2 strains into NP-2/CD4 cells expressing APJ .
|
-
- HY-N3506
-
|
HIV
|
Infection
Inflammation/Immunology
Cancer
|
Wilfortrine is a bioactive sesquiterpene alkaloid. Wilfortrine exhibits immunosuppresive effects. Wilfortrine also can inhibit leukaemia cell growth in mice and shows anti-HIV activity .
|
-
- HY-134809
-
CADA
|
HIV
|
Infection
Inflammation/Immunology
|
Cyclotriazadisulfonamide (CADA) is a specific CD4-targeted HIV entry inhibitors. Cyclotriazadisulfonamide (CADA) inhibits the co-translational translocation of human CD4 (huCD4) into the ER lumen in a signal peptide (SP)-dependent way. Cyclotriazadisulfonamide is also a Sec61 translocon inhibitor .
|
-
- HY-10046
-
AMD 3100; JM3100; SID791
|
CXCR
HIV
|
Infection
Inflammation/Immunology
Endocrinology
Cancer
|
Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM .
|
-
- HY-15353
-
MKC-442
|
HIV
|
Infection
Inflammation/Immunology
|
Emivirine (MKC-442) is a non-nucleoside reverse transcriptase inhibitors (NNRTIs) with Ki values of 0.20 and 0.01 μM for dTTP- and dGTP-dependent DNA or RNA polymerase activity, respectively. Emivirine displays potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity .
|
-
- HY-122470
-
|
Reverse Transcriptase
HIV
|
Infection
|
Stampidine is a nucleoside reverse transcriptase inhibitor (NRTI) with potent and broad-spectrum anti-HIV activity. Stampidine inhibits the laboratory HIV-1 strain HTLVIIIB (B-envelope subtype) and primary clinical isolates with IC50s of 1 nM and 2 nM, respectively. Stampidine also inhibits NRTI-resistant primary clinical isolates and NNRTI-resistant clinical isolates with IC50s of 8.7 nM and 11.2 nM, respectively .
|
-
- HY-B2237A
-
|
Bacterial
HIV
|
Infection
|
Lysozyme chloride is a bactericidal enzyme, and it lyses gram-positive bacteria. Lysozyme chloride can also be used for the research of HIV infection and pulmonary emphysema .
|
-
- HY-P1064
-
|
Apelin Receptor (APJ)
HIV
|
Infection
Cardiovascular Disease
Metabolic Disease
|
Apelin-36(human) is an endogenous orphan G protein-coupled receptor APJ agonist, with an EC50 of 20 nM. Apelin-36(human) shows high affinity to human APJ receptors expressed in HEK 293 cells (pIC50=8.61). Apelin-36 has been linked to two major types of biological activities: cardiovascular and metabolic. Apelin-36(human) inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ .
|
-
- HY-136703
-
|
HIV Protease
|
Infection
|
Lopinavir Metabolite M-1, an active metabolite of Lopinavir, inhibits HIV protease with a Ki of 0.7 pM. Lopinavir Metabolite M-1 has antiviral activities in vitro .
|
-
- HY-121370
-
|
HIV
Endogenous Metabolite
|
Others
|
α-D-Galactose is a non-starch polysaccharide isolated from the bulb tissues of Lilium davidii var. unicolor Salisb. α-D-Galactose has anti-oxidation properties, anti-tumour activities, immunomodulatory effects and anti-HIV functions .
|
-
- HY-114597
-
|
HIV
CRM1
|
Cancer
|
PKF050-638 is a potent and selective inhibitor of HIV-1 Rev (IC50=0.04 μM). PKF050-638 inhibits the CRM1-mediated Rev nuclear export by disrupting CRM1-NES interaction .
|
-
- HY-N8361
-
|
HIV
Apoptosis
|
Infection
Cancer
|
Glycoborinine, a natural carbazole alkaloid, can be isolated from Glycosmis pentaphylla. Glycoborinine induces HepG2 cell apoptosis through mitochondrial pathway. Glycoborinine also inhibits HIV replication in cells .
|
-
- HY-P1064A
-
|
HIV
Apelin Receptor (APJ)
|
Infection
Cardiovascular Disease
Metabolic Disease
|
Apelin-36(human) TFA is an endogenous orphan G protein-coupled receptor APJ agonist, with an EC50 of 20 nM. Apelin-36(human) TFA shows high affinity to human APJ receptors expressed in HEK 293 cells (pIC550=8.61). Apelin-36(human) TFA has been linked to two major types of biological activities: cardiovascular and metabolic. Apelin-36(human) TFA inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ .
|
-
- HY-10046R
-
|
CXCR
HIV
|
Infection
Inflammation/Immunology
Endocrinology
Cancer
|
Plerixafor (Standard) is the analytical standard of Plerixafor. This product is intended for research and analytical applications. Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM .
|
-
- HY-10493R
-
|
Cytochrome P450
HIV
|
Infection
Cancer
|
Cobicistat (Standard) is the analytical standard of Cobicistat. This product is intended for research and analytical applications. Cobicistat is a potent and selective inhibitor of cytochrome P450 3A (CYP3A) enzymes with IC50s of 30-285 nM. Cobicistat is a pharmacokinetic enhancer which increases the overall absorption of several HIV medications.
|
-
- HY-15899
-
|
HIV Protease
HIV
Drug Metabolite
|
Infection
|
Des(benzylpyridyl) Atazanavir (compound M1) is a N-dealkylation product of Atazanavir (HY-17367) metabolite. Atazanavir is a highly selective HIV-1 protease inhibitor. Des(benzylpyridyl) Atazanavir may contribute to the effectiveness Atazanavir but also to the toxicity and interactions. Des(benzylpyridyl) Atazanavir can be used for further research of Atazanavir effects .
|
-
- HY-120427
-
NSC 658586
|
CCR
HIV
|
Infection
|
Cosalane (NSC 658586) is a potent inhibitor of HIV replication. Cosalane has an intrinsic ability to block human and murine CCR7 function in vitro in response to both of its natural ligands, CCL19 and CCL21, with the IC50 of 0.207/2.66 μM in human for CCL19/CCL21 and 0.193/1.98 μM in murine, respectively .
|
-
- HY-133937
-
|
Bacterial
HIV
|
Infection
|
Sulfametrole is an orally active and potent antibacterial. Sulfametrole can be used for infections research, such as HIV, severe pneumonia and UTIs (urinary tract infections) .
|
-
- HY-10493S
-
GS-9350-d8
|
Isotope-Labeled Compounds
HIV
Cytochrome P450
|
Infection
|
Cobicistat-d8 (GS-9350-d8) is a deuterated version of Cobicistat (HY-10493). Cobicistat is a potent and selective inhibitor of cytochrome P450 3A (CYP3A) with IC50 values of 30-285 nM. Cobicistat is a pharmacokinetic enhancer that enhances the absorption of anti-HIV active molecules .
|
-
- HY-B0689
-
MK-639 free base; L-735524 free base
|
HIV
HIV Protease
Apoptosis
MMP
SARS-CoV
|
Inflammation/Immunology
Cancer
|
Indinavir (MK-639 free base) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir is also a SARS-CoV 3CL pro inhibitor .
|
-
- HY-B2237
-
|
Bacterial
HIV
|
Infection
|
Lysozyme from chicken egg white is a bactericidal enzyme, and it lyses gram-positive bacteria.
Lysozyme from chicken egg white can also be used for the research of HIV infection and pulmonary emphysema .
|
-
- HY-12926
-
|
HIV
HDAC
DNA/RNA Synthesis
|
Infection
|
ST7612AA1 is a histone deacetylase (HDAC) inhibitor that controls chromatin condensation and DNA transcription by removing acetyl groups from histones. ST7612AA1 is also a potent HIV reactivation inducer, and its reactivation activity is exerted without activating or proliferating CD4+T cells, and can be used in the study of HIV reactivation strategies and elimination of viral reservoirs .
|
-
- HY-B0689A
-
MK-639; L735524
|
HIV
HIV Protease
SARS-CoV
Apoptosis
MMP
|
Infection
Cancer
|
Indinavir sulfate (MK-639) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir sulfate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate is also a SARS-CoV 3CL pro inhibitor .
|
-
- HY-N12125
-
|
Others
|
Infection
|
Entadamide A (compound 1) is a tryptophan derivative. Entadamide A prevents tryptophan depletion by inhibiting indoleamine 2, 3-dioxygenase (IDO), thereby inhibiting HIV replication. Entadamide A can be used in drug and neuropsychiatric studies of redesivir [1].
|
-
- HY-B0689B
-
MK-639 ethanolate; L735524 ethanolate
|
Apoptosis
MMP
HIV
HIV Protease
SARS-CoV
|
Infection
Cancer
|
Indinavir sulfate ethanolate (MK-639 ethanolate) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir sulfate ethanolate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate ethanolate is also a SARS-CoV 3CL pro inhibitor .
|
-
- HY-B1422
-
Aminacrine
|
Bacterial
HIV
|
Infection
|
9-Aminoacridine, a fluorescent probe, acts as an indicator of pH for quantitative determination of transmembrane pH gradients (inside acidic). 9-Aminoacridine is an antimicrobial. 9-Aminoacridine exerts its antimicrobial activity by interacting with specific bacterial DNA and disrupting the proton motive force in K. pneumoniae. 9-Aminoacridine is a HIV-1 inhibitor and inhibits HIV LTR transcription highly dependent on the presence and location of the amino moiety. 9-Aminoacridine inhibits virus replication in HIV-1 infected cell lines. 9-Aminoacridine is used as a Rifampin (RIF; HY-B0272) adjuvant for the multidrug-resistant K. pneumoniae infections .
|
-
- HY-D0976
-
|
P2X Receptor
HIV
|
Infection
|
NF279 is a potent selective and reversible P2X1 receptor antagonist, with an IC50 of 19 nM. NF279 displays good selectivity over P2X2, P2X3 (IC50=1.62 μM), P2X4 (IC50>300 μM). NF279 is a dual HIV-1 coreceptor inhibitor that interferes with the functional engagement of CCR5 and CXCR4 by Env .
|
-
- HY-118731
-
|
Reverse Transcriptase
|
Infection
|
TNK-6123 is a potent Emivirine (HY-15353) analogue with improved activity against drug-resistant HIV mutants. TNK-6123 improves activity against Lys103Asn mutant RT .
|
-
- HY-P10685
-
[Tyr5,12,Lys7]-Polyphemusin II
|
HIV
CMV
|
Infection
|
T-22 (polyphemusin II with [Tyr5,12,Lys7]) is a new synthetic peptide that fights HIV, with an EC50 of 0.008 μg/mL and a CC50 of 54 μg/mL. T22 promotes plant height, photosynthesis, total chlorophyll content, and gas exchange in tomatoes, and it can resist CMV .
|
-
- HY-P2251
-
|
HIV
Microtubule/Tubulin
|
Infection
Inflammation/Immunology
Cancer
|
T-peptide, a Tuftsin analog, can be used for the research of human immunodeficiency virus (HIV) infection. T-peptide prevents cellular immunosuppression and improves survival rate in septic mice. T-peptide also can inhibit the growth of residual tumor cells after surgical resection .
|
-
- HY-P10820
-
|
HIV
|
Infection
|
N36Mut(e,g) is a gp41-targeted HIV fusion peptide inhibitor. N36Mut(e,g) acts by disrupting the homotrimeric coiled-coil of N-terminal helices in the pre-hairpin intermediate to form heterotrimers .
|
-
- HY-B1422R
-
|
Bacterial
HIV
|
Infection
|
9-Aminoacridine (Standard) is the analytical standard of 9-Aminoacridine. This product is intended for research and analytical applications. 9-Aminoacridine, a fluorescent probe, acts as an indicator of pH for quantitative determination of transmembrane pH gradients (inside acidic). 9-Aminoacridine is an antimicrobial. 9-Aminoacridine exerts its antimicrobial activity by interacting with specific bacterial DNA and disrupting the proton motive force in K. pneumoniae. 9-Aminoacridine is a HIV-1 inhibitor and inhibits HIV LTR transcription highly dependent on the presence and location of the amino moiety. 9-Aminoacridine inhibits virus replication in HIV-1 infected cell lines. 9-Aminoacridine is used as a Rifampin (RIF; HY-B0272) adjuvant for the multidrug-resistant K. pneumoniae infections .
|
-
- HY-P4108
-
|
Influenza Virus
|
Infection
|
TAT-HA2 Fusion Peptide is a peptide-based delivery agent that combines the pH-sensitive HA2 fusion peptide from Influenza and the cell-penetrating peptide TAT from HIV. TAT-HA2 Fusion Peptide is a transactivator of transcription and hemaglutanin for endosomal release. TAT-HA2 Fusion Peptide enhances cellular uptake of macromolecules .
|
-
- HY-10574
-
R278474; TMC278; DB08864
|
HIV
Reverse Transcriptase
|
Infection
|
Rilpivirine (R278474) is a potent and specific diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI). Rilpivirine has high antiviral activity against wild-type HIV (EC50=0.4 nM) and mutant viruses (EC50=0.1-2.0 nM). Rilpivirine has a high genetic barrier to resistance development of HIV .
|
-
- HY-10574A
-
TMC-278 hydrochloride; TMC278 hydrochloride; TMC 278 hydrochloride
|
SARS-CoV
MMP
|
Infection
|
Rilpivirine (R278474) hydrochloride is a potent and specific diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI). Rilpivirine hydrochloride has high antiviral activity against wild-type HIV (EC50=0.4 nM) and mutant viruses (EC50=0.1-2.0 nM). Rilpivirine hydrochloride has a high genetic barrier to resistance development of HIV .
|
-
- HY-135330
-
|
HIV
Reverse Transcriptase
|
Infection
|
Lamivudine- 13C, 15N2 is a labelled impurity of Lamivudine (BCH-189). Lamivudine is a nucleoside reverse transcriptase inhibitors (NRTIs), and can inhibit HIV reverse transcriptase 1/2 and the reverse transcriptase of hepatitis B virus .
|
-
- HY-123330
-